API
< Back to all clusters
[HEALTH] · Israel, United States · 9 sources

started · updated

Viagra's active ingredient sildenafil shown to limit cancer metastasis in preclinical study

Researchers at the Weizmann Institute of Science in Israel, together with collaborators from the United States, published a study in the journal Cancer Research showing that sildenafil, the active component of Viagra, can impede cancer metastasis. The drug blocks the enzyme phosphodiesterase‑5 (PDE5), raising cellular cGMP levels and trapping cholesterol inside lysosomes, which deprives tumor cells of a key resource needed for migration and formation of secondary tumors. Laboratory experiments in mouse models and human cancer cell cultures demonstrated reduced metastatic spread, and analysis of health records from about five million patients over two decades suggested a correlation between sildenafil use (especially when combined with statins) and improved survival.

The research team, led by Professor Ayelet Erez and Dr. Yarden Ariav, emphasized that the findings are pre‑clinical. Clinical trials are required before sildenafil could be considered a therapeutic option for cancer patients. The study points to a novel strategy of targeting cholesterol metabolism in tumor cells, potentially enhancing the anti‑metastatic effect when paired with cholesterol‑lowering statins.

Entities

Ayelet Erez · Cancer Research · Cancer Research (journal) · National Cancer Institute · Sildenafil · Sildenafil (Viagra) · Weizmann Institute of Science · Yarden Ariav

Claims

What the coverage asserts, and how many sources carry each claim.